Biolink and Immunofoco Sign Strategic Cooperation Agreement to Co-Build a Domestic Gene and Cell Therapy Platform

In recent years, the discussion around topics in the life sciences field has continued to rise, especially regarding the emerging industry of cell and gene therapy, which has attracted significant attention due to its rapid development. However, the production process platforms for cell and gene therapy have long been dominated by imported products, with many technologies still facing restrictions, urgently requiring a breakthrough.

On August 8, "Crossing-New Life" forum hosted by Immunofoco, and co-organized by BOHE Innovation and Yihong Business SchoolImmunityAt the ceremony for the industrialization path of cell drugs breaking through solid tumors and the inauguration of Immunofoco's pilot base, Dr. Wang Zhi, General Manager of Bailinke Pharmaceutical Technology, and Mr. Shen Qingshan, Co-founder and Vice President of Quality and Production Operations at Shenzhen Immunofoco Biotechnology Co., Ltd., signed a strategic cooperation agreement as representatives of their respective companies to jointly advance China’s "intelligent" manufacturing gene and cell therapy bioprocessing platform. Mr. Chen Zhi, Chairman of Bailinke Pharmaceutical Technology, and Ms. Sun Minmin, CEO of Immunofoco, also attended and witnessed this significant moment.

(From left to right: Mr. Shen Qingshan, Co-founder and Vice President of Quality & Production Operations at Immunofoco, Ms. Sun Minmin, CEO of Immunofoco, Mr. Chen Zhi, Chairman of BIO-LINK, and Dr. Wang Zhi, General Manager of BIO-LINK)

As a high-tech enterprise group providing process solutions for the life sciences sector, BIO-LINK is committed to continuously delivering high-quality innovative products and solutions to customers, creating an efficient, safe, and competitive biopharmaceutical supply chain ecosystem. This strategic cooperation with Immunofoco, which focuses on breakthroughs in solid tumor treatments, to jointly build a new domestic platform for gene and cell therapy, represents a strategic step toward fully realizing China's "smart" manufacturing in this industry.

Powerful Collaboration Opens Up More Possibilities for Gene and Cell Therapy in China

According toStatistics, In 2020, China reported new casesColorectal Cancer555,000 patients, 286,000 deaths; new casesGastric CancerThere were 479,000 patients and 374,000 deaths. Both the number of new cases and deaths rank first globally and are showing an increasing trend. Tumor recurrence and metastasis are the main causes of death in cancer patients. About 40%-50% of gastric cancer and colorectal cancer cases result in liver metastasis, and more than half of gastric cancer patients develop peritoneal metastasis. The efficacy of existing drug treatments is limited and does not sufficiently meet the clinical needs of patients.

Therefore, Immunofoco, as an innovative biotechnology company in the cell and gene therapy field in recent years, is committed to developing breakthrough treatments for solid tumors, bringing long-term survival benefits to patients.Immunocyte TherapyDrug. Core members of Immunofoco successfully promoted China's firstCAR-TThe drug's marketing application has rich experience in the development and industrialization of cellular medicines.

BIO-LINK, which focuses on the research, development, and manufacturing of critical process equipment and consumables for recombinant protein drugs, vaccines, antibody drugs, cell therapy, gene therapy, and other biologics, offers products that cover upstream cell culture, single-use fluid handling and storage, as well as downstream chromatography, ultrafiltration, filtration, and process development services in bioprocessing. Since its establishment in April 2021, BIO-LINK has rapidly developed, building production bases for single-use biopharmaceutical fluid handling and storage consumables, a full range of chromatography media, bioprocess hardware, filtration products, and a research and development center. Its products have now been adopted by several well-known biopharmaceutical companies in China, being applied in the research and production of antibodies, vaccines, recombinant protein drugs, and more.

The Immunofoco pilot R&D base, which carries this strategic cooperation, was built in accordance with the requirements of China's NMPA GMP for clinical research drugs and also referenced those of the United States.FDAand the EU EMA for CGT products and ATMPsGuidelines, which can meet the needs of Immunofoco's cell therapy product IND application and the preparation of exploratory clinical medications. BIO-LINK will assign a dedicated team to collaborate closely with Immunofoco’s team to customize a professional platform tailored to industry needs. Together, they will empower and accelerate the incubation of industrial projects, achieving more efficient, high-quality, and affordable production.

Solving Technical Challenges, Achieving Life Innovations Through Technology

In addition to exploring the latest advances in CAR-T therapy for gastric cancer, other key themes of this strategic conference include regulatory frameworks for the industrialization of cell therapy drugs, innovative market access and commercial insurance support for cell therapies, fundamental concepts and applications of innovative payment models, opportunities and pathways for the localization of core process equipment in cell and gene therapy, and the role of single-use bioprocessing technologies in efficiently establishing pilot platforms for cell therapy.

Science and technology are the primary productive forces. In the past decade, the new technology revolution has revealed its extremely important position in the formation and development of productive forces, which cannot be underestimated in any industry. Therefore, the new attempt by BIO-LINK and Immunofoco will genuinely focus on resolving the long-standing issue of "technological bottlenecks," taking a solid step toward the comprehensive realization of China-produced cell and gene therapy, promoting the development of China-produced cell and gene therapy drugs.

In the future, BIO-LINK will continue to uphold its mission of "empowering biotechnology and unlocking infinite possibilities" by providing high-quality, safe, easily verifiable, cost-effective, and supply-chain-secured Chinese "smart" manufactured biopharmaceutical comprehensive solutions for the biologics industry. At the same time, BIO-LINK will actively seek and promote upstream and downstream collaborations in the life sciences field, working together with like-minded partners to accelerate the industrial development of biopharmaceuticals and build a healthier and better world.

Recommended related conferences: